Table 5.

Association of female menopausal hormone use with endometrial cancer among women age ≥40 years, stratified by obesity status, 1995–2013a

Non-obese (BMI < 30 kg/m2)Obese (BMI ≥ 30 kg/m2)
CasesRatebIRRc95% CICasesRatebIRRc95% CI
Estrogen-only FMH used
 Nevere3265.41.00Referent71188.41.00Referent
 Ever10173.73.051.44–6.467172.90.990.44–2.24
  Former6156.82.501.01–6.17399.20.500.15–1.63
  Current4207.35.051.42–18.034389.95.161.51–17.58
Estrogen + progestin FMH usef
 Nevere3265.41.00Referent71188.41.00Referent
 Ever1163.61.000.47–2.1012121.10.620.33–1.19
  Former551.40.730.27–1.9410156.00.650.33–1.30
  Current679.51.650.55–4.93257.20.480.09–2.47
  • aAnalysis restricted to women ≥40 years of age, not taking oral contraceptives, with known menopause status, and not reporting use of multiple FMH types.

  • bMultivariable model stratified by age and study period and adjusted for age at menarche, parity, menopausal status, oral contraceptive use, smoking, body mass index (continuous), and vigorous physical activity.

  • cCrude rate per 100,000 person-years.

  • dAdditionally adjusted for estrogen plus progestin FMH use.

  • eNever reported any FMH use.

  • fAdditionally adjusted for estrogen-only FMH use.